Last reviewed · How we verify
NCT03623217
Quality of Life Questionnaire Validation for Patients With Changed Tacrolimus Dosing After Kidney Transplantation
trial testing Qualitative interviews with participants in Kidney Transplantation in 56 participants. Completed in 17 October 2017.
17 October 2017
Quick facts
| Lead sponsor | Astellas Pharma Korea, Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 56 |
| Start date | 24 February 2015 |
| Primary completion | 17 October 2017 |
| Estimated completion | 17 October 2017 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Qualitative interviews with participants
Conditions studied
- Kidney Transplantation — all drugs for Kidney Transplantation →
Sponsor
Astellas Pharma Korea, Inc. — full company profile →
Who can join
Adults 19 to 69, any sex, with Kidney Transplantation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to develop and validate a questionnaire to assess the quality of life when the recipients of kidney transplantation switched their medication from tacrolimus twice daily (BID regimen) to Advagraf (once daily (QD) regimen of modified release tacrolimus).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Development and validation of the Kidney Transplantation and Quality of Life, a Korean questionnaire to assess the general quality of life and other health issues associated with medication change in kidney transplant recipients.
Rhu J, Lee KW, Chung YJ, Park JB, et al · · 2019 · cited 3× · PMID 35769972 · DOI 10.4285/jkstn.2019.33.4.135
Verify or expand the search:
- PubMed search for NCT03623217
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplantation
Currently open trials in the same condition.
- NCT07275632 — The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients · Phase 1, PHASE2 · recruiting
- NCT06568549 — Reduced Immunosuppression in Older Renal Transplant Recipients With Trugraf®/TRAC Monitoring (RIOT Trial): A Prospective · Phase 4 · recruiting
- NCT06829719 — TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation · NA · recruiting
- NCT07316829 — TRAnscriptional Profile of Peripheral Blood Cells in Patient With Chronic Kidney and Lung Rejection: Correlation With Re · active not recruiting
- NCT06886256 — Prehabilitation for Kidney Transplant Candidates · NA · recruiting
Other Astellas Pharma Korea, Inc. trials
Trials by the same sponsor.
- NCT06902545 — A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With Gastric or Gastroesophageal Junction · recruiting
- NCT06452212 — Non-Interventional Study to Establish Consensus on Management of Metastatic Hormone-Sensitive Prostate Cancer Patients · completed
- NCT06011954 — A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection · recruiting
- NCT04691648 — A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Li · completed
- NCT03737708 — A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03623217 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Astellas Pharma Korea, Inc.
- Last refreshed: 21 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03623217.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing